IRIS
RIZZI, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.968
EU - Europa 2.676
AS - Asia 1.261
SA - Sud America 9
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 12.928
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.959
CN - Cina 938
IT - Italia 681
SE - Svezia 654
UA - Ucraina 435
DE - Germania 314
FI - Finlandia 243
SG - Singapore 223
GB - Regno Unito 140
FR - Francia 92
IE - Irlanda 43
IN - India 36
BE - Belgio 22
HK - Hong Kong 19
CZ - Repubblica Ceca 18
RU - Federazione Russa 11
IR - Iran 10
TR - Turchia 8
KR - Corea 6
PL - Polonia 6
CA - Canada 5
EU - Europa 5
AU - Australia 4
BR - Brasile 4
MX - Messico 4
NL - Olanda 4
VN - Vietnam 4
ES - Italia 3
KZ - Kazakistan 3
RO - Romania 3
TW - Taiwan 3
CO - Colombia 2
ET - Etiopia 2
ID - Indonesia 2
JP - Giappone 2
MA - Marocco 2
PH - Filippine 2
TH - Thailandia 2
AL - Albania 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CL - Cile 1
DK - Danimarca 1
HR - Croazia 1
IL - Israele 1
MD - Moldavia 1
MK - Macedonia 1
PE - Perù 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 12.928
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.016
Chandler 1.011
Woodbridge 893
Fairfield 825
Ashburn 536
Houston 512
Nyköping 470
Ann Arbor 454
Cambridge 431
Seattle 321
Wilmington 294
Roxbury 256
Lawrence 241
Nanjing 239
Singapore 189
Boardman 171
Des Moines 161
Beijing 146
Bari 130
New York 124
Inglewood 107
Princeton 89
Shenyang 71
Hebei 66
San Diego 55
Rome 53
Dearborn 51
Jiaxing 51
Santa Clara 49
Brooklyn 48
Nanchang 45
Los Angeles 44
Dublin 42
Changsha 39
Tianjin 37
Paris 34
London 32
Guangzhou 27
Pune 25
Florence 24
Redwood City 22
Brussels 21
Milan 19
Jinan 17
Noicattaro 16
Washington 16
Helsinki 14
Kunming 14
Norwalk 13
West Jordan 13
Wuhan 13
Hefei 12
Ningbo 12
Shanghai 12
Augusta 11
Auburn Hills 10
Brno 10
Leawood 10
Ardabil 9
Orta Nova 9
Nuremberg 8
San Mateo 8
Boydton 7
Chiswick 7
Melito Di Napoli 7
Munich 7
Zhengzhou 7
Fuzhou 6
Kilburn 6
Marseille 6
Omice 6
Yiwu 6
Bengaluru 5
Brescia 5
Indiana 5
Monmouth Junction 5
Naples 5
Radomsko 5
Torino 5
Trani 5
Triggiano 5
Alcamo 4
Bologna 4
Dong Ket 4
Grafing 4
Imbersago 4
Modugno 4
Moscow 4
Napoli 4
Noto 4
Taizhou 4
Tappahannock 4
Turin 4
Balıkesir 3
Baotou 3
Bitonto 3
Cerignola 3
Giovinazzo 3
Grottaglie 3
Istanbul 3
Totale 9.877
Salva come PNG Salva come JPEG
Nome #
Leucemia linfatica cronica in trasformazione prolinfocitoide: descrizione di un caso 158
LIGHT/TNFSF14 as a new biomarker of bone disease in multiple myeloma patients experiencing therapeutic regimens 108
TRAIL effect on osteoclast formation in physiological and pathological conditions 106
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials 105
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese" 103
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients 102
Vascular Endothelial Growth Factor Serum Levels Are Elevated in Patients with Hereditary Hemorrhagic Telangiectasia 98
Light/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease. 98
Amyloid in bone marrow smears of patients affected by multiple myeloma 96
Non-treatment-related chronic myeloid leukemia as a second malignancy 95
Behçet's disease: an immune-mediated vasculitis involving vessels of all sizes 94
A case of AL amyloidosis associated with IgD multiple myeloma (MM): clinical and laboratory findings, and outcome 92
Sclerostin is overexpressed by plasma cells from multiple myeloma patients 91
Rhabdomyolysis and acute tubular necrosis in coniine (hemlock)poisoning 91
Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature 90
Autoimmune hemolytic anemia during interferon-alfa therapy for chronic hepatitis C 89
Autoimmune Myelofibrosis: report of three cases and review of the literature 89
In vitro osteoclastogenesis and T-cell RANKL expression in multiple myeloma-bone disease at diagnosis and in the setting of frontline treatment 88
Takayasu’s arteritis: a cell mediated large vessel vasculitis 87
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 86
Hepatitis C virus infection and mixed cryoglobulinemia: a striking association 84
A role of light as potential biomarker for progression of smoldering to symptomatic multiple myeloma 83
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 83
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 81
Malignant lymphoma involving a Warthin’s tumor: a case with immunophenotypic and gene rearrangement analysis 80
CD34CD2 Acute promyelocytic leukemia (APL): is this a distinct subset? 80
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 78
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study 77
A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up 75
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide 74
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 74
Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients 74
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia 73
Infection complications in patients with multiple myeloma treated with new drug combinations including thalidomide 73
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I–II GIMEMA trial 73
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 73
Alteration of the osteogenic properties of bone marrow stromal cells from multiple myeloma bone disease patients 72
Anti-endothelial cell antibodies (AECA) in a patient wiyh Takayasu’s arteritis. In: Pathogenesis and immunotherapy of autoimmune diseases. Final program and abstract book 72
Ibridizzazione in situ non isotopica. Attualità e prospettive 72
Schnitzler's syndrome: diagnosis, treatment, and follow-up. 72
The Role of LIGHT in Multiple Myeloma-Bone Disease 72
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma 72
Alteration of bone remodeling in multiple myeloma bone disease: role of sclerostin 68
The role of multiparameter flow cytometry in the work-up of IGM-monoclonal gammopathies 68
A weekly infusion of bortezomib reduces peripheral neuropathy 68
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase 67
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction 67
Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? 67
Amyloidosis: clinical picture, immunological and biomolecular features, treatment prospects 66
The OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease 66
Myeloma cells suppress osteoblasts through sclerostin secretion 66
Clinical spectrum of accidental hemlock poisoning: neurotoxic manifestations, rhabdomyolysis and acute tubular necrosis 65
A phase II Study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis 65
A case of light chain (AL) amyloidosis associated with IgD Multiple Myeloma (MM): clinical features, laboratory findings and outcome 65
null 65
Analysis of percent identity of IGHV mutation as prognostic factor in CLL patients treated with fludarabine, cyclofosfamide and rituximab: a single centre experience 65
Exploratory survey on multiple myeloma patients' perception 64
T cells support the osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease 63
Acute tubular necrosis in the hemlock poisoning 63
Aneurysms of the supra-aortic trunks in Takayasu's disease - Report of two cases 63
Livelli sierici di VEGF in pazienti affetti da Sindrome di Rendu-Osler-Weber 63
Physician-Patient relationship: intervention opportunities for multiple myeloma patients'needs 63
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 63
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the ‘Rete Ematologica Pugliese E Basilicata’ 63
Bendamustine, Bortezomib and Dexamethasone (BVD) in patients with relapsed-refractory multiple myeloma (MM): updated results of a multicenter phase II study. 62
Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature 62
Alterazione delle capacità osteogeniche in cellule stromali ottenute da midollo osseo di pazienti affetti da mieloma multiplo 61
T cells support osteoclastogenesis in an in vitro model derived from psoritic arthritis 61
Another link between bone and immune system: LIGHT 61
FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia 61
L'AMILOIDOSI: QUADRI CLINICI, CARATTERISTICHE IMMUNOLOGICHE E BIOMOLECOLARI, PROSPETTIVE TERAPEUTICHE 60
T cells support the in vitro formation of osteoclasts in multiple myeloma-bone disease: the role of OPG/TRAIL interaction 60
Altered osteogenic properties of bone marrow stromal cells from multiple myeloma patients 60
Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenstrom Macroglobulinemia 59
Kidney damage by ingestion of ethylene glicol 58
Anti-endothelial cell antibodies in Wegener’s granulomatosis and micropolyarteritis 58
Angiogenesis and hereditary hemorrhagic telangiectasia. Rendu-Osler-Weber disease 58
Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment 57
FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience 57
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens 57
A phase II study of chlorambucil + rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results 57
Enoxaparin, aspirin, or warfarin for thromboprophilaxis in newly diagnosed myeloma patients receiving thalidomide: a randomized controlled trial 56
Microvessel density and angiogenic cytokine expression in autoimmune myelofibrosis compared with chronic idiopathic myelofibrosis 56
Thalidomide, dexamethasone, doxil and velcade (ThaDD-V) induction therapy followed by consolidation-maintenance is very effective in early relapsed/refractory MM 56
P-ANCA atipici nelle malattie infiammatorie croniche intestinali 56
Rhabdomyolysis and acute tubular necrosis in hemlock poisoning 55
Soluble Decoy Receptor 3 (DcR3) modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients 55
Anticorpi monoclonali anti-idiotipo (Ab2) anti-CD4 inducono anticorpi anti-CD4 in un sistema singenico 55
ANALYSIS OF PROGNOSTIC FACTORS AND TIME TO FIRST TREATMENT IN YOUNG PATIENTS (<55 YEARS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE CENTER EXPERIENCE 55
The role of molecular genetics in the diagnosis of lymphoma 54
Autoimmune bone marrow fibrosis: a distinct clinicopathological entity 54
Antigene CD4 solubile nei preparati di immunoglobuline umane per vie endovenosa 54
Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience 54
Economic and social burden of multiple myeloma in Italy – Co.Mi.M. Study 54
CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP) 54
Anti-endothelial cell autoantibodies in patients with Behcet’s disease 53
Bone marrow angiogenesis in autoimmune myelofibrosis 53
Myeloma cells induce osteoblast suppression through sclerostin secretion 53
Anemia emolitica autoimmune sviluppata durante il trattamento di epatite cronica C con interferone-alfa 52
Anti-endothelial cell autoantibodies in Takayasu’s arteritis 52
Totale 7.106
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.430
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.430
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.916 0 0 49 166 261 151 325 174 314 131 302 43
2020/20211.949 197 63 167 68 306 101 234 126 204 242 151 90
2021/20221.790 78 253 7 128 56 77 73 96 126 79 314 503
2022/20232.648 380 231 111 271 344 375 41 300 495 16 45 39
2023/20241.333 200 212 73 66 97 238 66 69 8 55 101 148
2024/2025480 116 55 309 0 0 0 0 0 0 0 0 0
Totale 13.236